Advanced Supernova Stent Shows Promise for Stroke Treatment

In a groundbreaking development for stroke treatment, the Supernova Stent has been shown to be both safe and effective for patients suffering from severe strokes, according to results from a clinical trial led by the All India Institute of Medical Sciences (AIIMS) in Delhi. This trial, known as the GRASSROOT Trial, marks a significant milestone in advanced stroke care in India.

On December 13, 2023, experts from AIIMS announced that the Supernova Stent demonstrated promising results, indicating it could transform the treatment landscape for stroke patients in the country. Dr. Shailesh B. Gaikwad, Professor and Head of the Department of Neuroimaging & Interventional Neuroradiology at AIIMS and the National Principal Investigator of the GRASSROOT Trial, stated, “This trial is a turning point for stroke treatment in India.” He noted that preliminary findings published in the Journal of Neurointerventional Surgery revealed excellent safety and efficacy outcomes.

Breakthrough Results in Stroke Care

The GRASSROOT Trial is the first prospective multicentre thrombectomy trial to utilize the Supernova stent retriever, which has achieved a high success rate in restoring blood flow to the brain. The trial reported a brain bleed rate of just 3.1 percent and a mortality rate of 9.4 percent. Additionally, the results showed that 50 percent of participants achieved functional independence within 90 days post-procedure.

Designed specifically for the diverse patient population in India, the Supernova Stent addresses a pressing need. Strokes in India often affect younger individuals compared to Western countries. Earlier this year, the Central Drugs Standard Control Organisation (CDSCO) accepted data from the GRASSROOT trial, leading to the stent’s approval for routine use in India.

A Step Forward for Make-in-India Initiative

The GRASSROOT Trial was conducted across eight medical centers, highlighting India’s growing capabilities in advanced medical technology. The success of this trial not only supports the Make-in-India initiative but also positions India as a key player in the global landscape of stroke treatment.

Dr. Dileep Yavagal, a Professor of Neurology and Neurosurgery at the University of Miami and part of the global trial, shared insights on the broader implications of the Supernova Stent. “The device has already treated more than 300 patients in Southeast Asia and is now set to be manufactured in India at affordable prices,” he stated. This development offers new hope to the approximately 1.7 million Indians who experience strokes annually.

The advancements from the GRASSROOT Trial represent not only a medical achievement but also a significant step toward improving healthcare accessibility and outcomes for stroke patients in India and beyond.